Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum

doi:10.1016/0306-4522(93)90238-B

Neuroscience

Volume 54, Issue 3, June 1993, Pages 669-680

https://doi.org/10.1016/0306-4522(93)90238-B Get rights and content

Abstract

Dopamine-mediated behaviors and certain biochemical and molecular events associated with these behaviors were examined following continuous infusion of the D₁dopamine agonist SKF38393 or the D₂dopamine agonist quinpirole into mice for six days. SKF38393 produced a transient grooming behavior while quinpirole initially induced stereotypy, which was followed by an increased locomotor behavior. Continuous infusion of quinpirole caused a significant down-regulation of striatal D₂dopamine receptors without significantly changing the density of D₁ receptors. This was accompanied by a decrease in the level of D₂ receptor messenger RNA in striatum as measured by Northern analysis. The down-regulation of dopamine receptors was selective for D₂ dopamine receptors, since treatment with SKF38393 had no significant effects on either D₁or D₂ dopamine receptors, nor did it alter the messenger RNAs for the D₁ and D₂ receptors. Continuous treatment with quinpirole resulted in a significant increase in striatal mu opioid receptor levels without significant changing delta opioid receptors. This treatment also induced a significant decrease in proenkephalin messenger RNA in striatum.

Taken together, these results suggest that the down-regulation of D₂ dopamine receptor and D₂ receptor messenger RNA is the result of the persistent stimulation of D₂ receptors and that the up-regulation of mu opioid receptors may be a compensatory response to a decreased biosynthesis of enkephalin. They suggest further that the biochemical and molecular changes that take place in dopaminergic and enkephalinergic systems following continuous treatment with dopamine agonists may underlie the mechanisms by which certain dopamine-mediated behaviors occur.

Reference (64)

AnguloJ.A. et al.
Regulation by dopaminergic neurotransmission of dopamine D₂ mRNA and receptor levels in the striatum and nucleus accumbens of the rat
Molec. Brain Res.
(1991)
BrittonD.R. et al.
Rapid reversal of denervation supersensitivity of dopamine D₁ receptor byl-dopa or a novel dopamine D₁ receptor agonist, A68930
Eur. J. Pharmac.
(1991)
ChenJ.F. et al.
Neuronal localization and modulation of the D₂ dopamine receptor mRNA in brain of normal mice and mice lesioned with 6-hydroxydopamine
Neuropharmacology
(1991)
ChenJ.F. et al.
Ontogenetic expression of D₂ dopamine receptor mRNA in rat corpus striatum
Devl Brain Res.
(1991)
CiminoM. et al.
Differential ontogenetic expression and regulation of proenkephalin and preprosomatostatin mRNA in rat caudate-putamen as studied by in situ hybridization histochemistry
Devl Brain Res.
(1991)
CivelliO. et al.
Molecular biology of the dopamine receptors
Eur. J. Pharmac.
(1991)
DawsonT.M. et al.
D₁ dopamine receptor in the rat brain: autoradiographic localization using [³H]-SCH23390
Eur. J. Pharmac.
(1985)
GossJ.R. et al.
Haloperidol treatment increases D₂ dopamine receptor protein independently of RNA levels in mice
Life Sci.
(1991)
GrahamW.C. et al.
Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D₂ but not D₁ receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat
Brain Res.
(1990)
GraybielA.M.
Neurotransmitters and neuromodulators in the basal ganglia
Trends Neurosci.
(1990)

MansourA. et al.

Anatomy of CNS opioid receptors

Trends Neurosci.

(1988)

MartinJ.R. et al.

Chronically administered morphine increased dopamine receptor sensitivity in mice

Eur. J. Pharmac.

(1986)

MissaleC. et al.

Repeated reserpine administration up-regulates the transduction mechanisms of D₁ receptors without changing the density of [³H]-SCH23390 binding

Brain Res.

(1989)

MorrisB.J. et al.

Dopaminergic regulation of striatal proenkephalin mRNA and prodynorphin mRNA: contrasting effects of D₁ and D₂ antagonists

Neuroscience

(1988)

MorrisB.J. et al.

Proenkephalin mRNA levels in rat striatum are increased and decreased, respectively, by selective D₂ and D₁ dopamine receptor antagonists

Neurosci. Lett.

(1991)

MunsonP.J. et al.

Ligand: a versatile computerized approach for characterization of ligand-binding systems

Analyt. Biochem.

(1980)

OlsonG.A. et al.

Endogenous opiates: 1989

Peptides

(1990)

SchoffelmeerA.N.M. et al.

Opioid and D₂ receptor mediated inhibition of forskolin-stimulated cyclic AMP efflux from rat neostriatal slices

Neuropharmacology

(1987)

TaylorM.D. et al.

Acute effects of D₁ and D₂ dopamine receptor agonist and antagonist drugs on basal ganglia [Met⁵]- and [Leu⁵]-enkephalin and neurotensin content in the rat

Biochem. Pharmac.

(1991)

TroveroF. et al.

Striatal opiate mu-receptors are not located on dopamine nerve endings in the rat

Neuroscience

(1990)

UkaiM. et al.

DAGO ([D-Ala²,N-Me-Phe⁴,Gly-ol]enkephalin) specifically reverses apomorphine-induced increase in rearing and grooming behaviors in the mouse

Brain Res.

(1991)

Van TolH.H.M. et al.

Lack of effect of chronic dopamine receptor blockade on D₂ dopamine receptor mRNA level

Neurosci. Lett.

(1990)

VaughnL.K. et al.

A high affinity, high selective ligand for the delta opioid receptor: [³H]-D-Pen²,pCl-Phe⁴,D-Pen⁵] enkephalin

Life Sci.

(1989)

WangH.-Y. et al.

Differential regulation of release of acetylcholine in the striatum in mice following continuous exposure to selective D₁ and D₂ dopaminergic agonists

Neuropharmacology

(1993)

WinklerJ.D. et al.

Selective down-regulation of D₁ dopaminc mediated rotational behavior in supersensitive mice

Neuropharmacology

(1988)

YoshikawaK. et al.

Rat brain proenkephalin mRNA: cDNA cloning, primary structure and distribution in the central nervous system

J. biol. Chem.

(1984)

AltarC.A. et al.

Computer-assisted video analysis of [³H]-spiroperidol binding autoradiography

J. Neurosci. Meth.

(1984)

BakerG.B. et al.

Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system

Cell. molec. Neurobiol.

(1989)

BoublikJ.H. et al.

Interaction of dopamine receptor ligand with subtypes of the opiate receptor

Eur. J. Pharmac.

(1985)

BreneS. et al.

Expression of dopamine D₂ receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudate-putamen

Expl Brain. Res.

(1990)

CarlssonA.

The current status of the dopamine hypothesis of schizophrenia

Neuropsychopharmacology

(1988)

ChesseletM.F. et al.

Morphine and δ opiate agonists locally stimulate in vivo dopamine release in cat caudate nucleus

Nature

(1981)

Cited by (118)

Psychedelics, OCD and related disorders: A systematic review
2024, Journal of Obsessive-Compulsive and Related Disorders
This systematic review analyzes the current literature on the potential therapeutic use of classic psychedelics (i.e., psilocybin, lysergic acid diethylamide [LSD], N,N-dimethyltryptamine [DMT], 5-methoxy-N,N-dimethyltryptamine [5-MeO-DMT], mescaline, and other classic psychedelic analogs utilized in preclinical models) in obsessive-compulsive disorder (OCD) and related disorders. Our search identified 23 articles meeting our predetermined eligibility criteria, comprising 2 non-systematic reviews, 11 preclinical studies investigating the use of classic psychedelics or analogs in preclinical models of OCD, 8 case studies or case reports, and 2 clinical trials. This review provides an up-to-date synthesis of psychedelic OCD research, bridging preclinical findings, historical case reports, and initial clinical trial outcomes. Psilocybin appears to be the most widely used classic psychedelic and is well-tolerated in both OCD and body dysmorphic disorder (BDD) populations, with some participants experiencing significant symptom reduction. This review contributes to our understanding of the potential of classic psychedelics (in particular LSD and psilocybin) as novel therapeutic interventions for OCD and related disorders, offering insights into future research directions and clinical applications in this emerging field.
Lower striatal dopamine D<inf>2/3</inf>receptor availability in obsessive-compulsive disorder: A meta-analysis of [<sup>11</sup>C]-raclopride and [<sup>123</sup>I]-IBZM studies
2021, Journal of Obsessive-Compulsive and Related Disorders
It is unclear whether striatal dopamine D_2/3 receptor (D_2/3R) availability is reduced in obsessive-compulsive disorder (OCD). We conducted a meta-analysis of substituted benzamide radiotracer studies to address this question (k = 4; N = 33 medication-free patients with OCD and N = 38 matched healthy controls). Our meta-analysis suggests that striatal D_2/3R availability is lower in medication-free patients with OCD compared to healthy controls (Cohen's d = 0.97, 95% CI = 0.45–1.50, z = 3.65, I² = 0, p < .0001). Previous studies have not been sufficiently powered to detect this observed effect-size. We recommend that future studies employ larger sample sizes (n ≥ 19 per group), composed of younger OCD patients with greater illness severity, to validate the findings of this meta-analysis. We hope these findings will help guide future dopamine imaging studies in OCD.
Antidepressant-like effects of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid receptor modulator, in a rat IFN-α-induced depression model
2018, Brain, Behavior, and Immunity
Citation Excerpt :
3CS-nalmefene is a potent mu receptor antagonist with low intrinsic agonist activity at kappa and delta opioid receptors when tested in cell lines expressing human opioid receptors. Humans share 94% sequence homology to rat mu, delta and kappa opioid receptors which has to be considered when applying opioid compounds to rat models (Chen et al., 1993; Meng et al., 1993; Fukuda et al., 1993). 3CS-nalmefene was designed based on concepts previously discussed by Wentland and colleagues (2009) of enhancing hydrophobic activity to increase opioid receptor activity in compound design.
Patients receiving the cytokine immunotherapy, interferon-alpha (IFN-α) frequently present with neuropsychiatric consequences and cognitive impairments. Patients (25–80%) report symptoms of depression, including, anhedonia, irritability, fatigue and impaired motivation. Our lab has previously demonstrated treatment (170,000 IU/kg sc, 3 times per week for 4 weeks) of the pro-inflammatory cytokine, IFN-α, induced a depressive phenotype in rats in the forced swim test (FST). Here, we examine the biological mechanisms underlying behavioral changes induced by IFN-α, which may be reflective of mechanisms underlying inflammation associated depression. We also investigate the potential of 3-carboxamido seco-nalmefene (3CS-nalmefene), a novel opioid modulator (antagonist at mu and partial agonist at kappa and delta opioid receptors in vitro), to reverse IFN-α induced changes. In vitro radioligand receptor binding assays and the [³⁵S] GTPγS were performed to determine the affinity of 3CS-nalmefene for the mu, kappa and delta opioid receptors. IFN-α treatment increased circulating and central markers of inflammation and hypothalamic–pituitaryadrenal (HPA) axis activity (IL-6, IL-1β and corticosterone) while increasing immobility in the FST, impairing of object displacement learning in the object exploration task (OET), and decreasing neuronal proliferation and brain-derived neurotrophic factor (BDNF) in the hippocampus. Treatment with 3CS-nalmefene (0.3 mg/kg/sc twice per day, 3 times per week for 4 weeks) prevented IFN-α-induced immobility in the FST and impaired object displacement learning. In addition, 3CS-nalmefene prevented IFN-α-induced increases in inflammation and hyperactivity of the HPA-axis, the IFN-α-induced reduction in both neuronal proliferation and BDNF expression in the hippocampus. Overall, these preclinical data would support the hypothesis that opioid receptor modulation is a relevant target for treatment of depression.
The dopamine D2/D3 receptor agonist quinpirole increases checking-like behaviour in an operant observing response task with uncertain reinforcement: A novel possible model of OCD
2014, Behavioural Brain Research
Excessive checking is a common, debilitating symptom of obsessive-compulsive disorder (OCD). In an established rodent model of OCD checking behaviour, quinpirole (dopamine D2/3-receptor agonist) increased checking in open-field tests, indicating dopaminergic modulation of checking-like behaviours.
We designed a novel operant paradigm for rats (observing response task (ORT)) to further examine cognitive processes underpinning checking behaviour and clarify how and why checking develops. We investigated i) how quinpirole increases checking, ii) dependence of these effects on D2/3 receptor function (following treatment with D2/3 receptor antagonist sulpiride) and iii) effects of reward uncertainty.
In the ORT, rats pressed an ‘observing’ lever for information about the location of an ‘active’ lever that provided food reinforcement. High- and low-checkers (defined from baseline observing) received quinpirole (0.5 mg/kg, 10 treatments) or vehicle. Parametric task manipulations assessed observing/checking under increasing task demands relating to reinforcement uncertainty (variable response requirement and active-lever location switching). Treatment with sulpiride further probed the pharmacological basis of long-term behavioural changes.
Quinpirole selectively increased checking, both functional observing lever presses (OLPs) and non-functional extra OLPs (EOLPs). The increase in OLPs and EOLPs was long-lasting, without further quinpirole administration. Quinpirole did not affect the immediate ability to use information from checking. Vehicle and quinpirole-treated rats (VEH and QNP respectively) were selectively sensitive to different forms of uncertainty. Sulpiride reduced non-functional EOLPs in QNP rats but had no effect on functional OLPs. These data have implications for treatment of compulsive checking in OCD, particularly for serotonin-reuptake-inhibitor treatment-refractory cases, where supplementation with dopamine receptor antagonists may be beneficial.
Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: Dopamine transporter occupancy as measured by PET
2014, European Neuropsychopharmacology
Tesofensine (TE) is a novel triple monoamine re-uptake inhibitor inducing a potent inhibition of the re-uptake process in the synaptic cleft of the neurotransmitters dopamine, norepinephrine, and serotonin. In recent preclinical and clinical evaluations TE showed a robust anti-obesity effect, but the specific mechanism of this triple monoamine re-uptake inhibitor still needs to be further elucidated. This positron emission tomography (PET) study, using [¹¹C]βCIT-FE, aimed to assess the degree of the dopamine transporter (DAT) occupancy, at constant TE plasma levels, following different oral, multiple doses of TE during totally 8–12 days. In addition, the relationships between DAT occupancy and TE plasma concentrations, or doses, were investigated to enable assessment of DAT occupancies in subsequent clinical trials. The results demonstrated that TE induced a dose-dependent blockade of DAT following multiple doses of 0.125–1 mg TE at anticipated steady-state conditions. The mean striatal DAT occupancy varied dose-dependently between 18% and 77%. A sigmoid E_max model well described the relationship between striatal DAT occupancy and TE plasma concentrations or doses. It was estimated that the maximum achievable DAT occupancy was about 80% and that half of this effect was accomplished by approximately 0.25 mg TE and a plasma drug concentration of 4 ng/ml. The results indicated an important mechanism of action of TE on DAT. Further, these results suggest that the previously reported dose-dependent weight loss, in TE treated subjects, was in part mediated by an up-regulation of dopaminergic pathways due to enhanced amounts of synaptic dopamine after blockade of DAT.
Pharmacogenetics of chronic pain management
2014, Clinical Biochemistry
Citation Excerpt :
Animal studies have demonstrated reduced neuronal enkephalin content in the brain with chronic activation of dopaminergic transmission. The reduced enkephalin content has been shown to be followed by an upregulation of the opioid-μ receptor [52,53]. The lower doses of morphine required by individuals with the Met158 variant may be explained by reduced COMT activity which is associated with increased dopaminergic stimulation, resulting in upregulation of opioid-μ receptor expression in the brain, making morphine more effective.
The experience of chronic pain is one of the commonest reasons individuals seek medical attention, making the management of chronic pain a major issue in clinical practice. Drug metabolism and responses are affected by many factors, with genetic variations offering only a partial explanation of an individual’s response. There is a paucity of evidence for the benefits of pharmacogenetic testing in the context of pain management.
We reviewed the literature between 2000 and 2013, and references cited therein, using various keywords related to pain management, pharmacology and pharmacogenetics.
Opioids continue to be the mainstay of chronic pain management. Several non-opioid based therapies, such as treatment with cannabinoids, gene therapy and epigenetic-based approaches are now available for these patients. Adjuvant therapies with antidepressants, benzodiazepines or anticonvulsants can also be useful in managing pain. Currently, laboratory monitoring of pain management patients, if performed, is largely through urine drug measurements.
Drug half-life calculations can be used as functional markers of the cumulative effect of pharmacogenetics and drug–drug interactions. Assessment of half-life and therapeutic effects may be more useful than genetic testing in preventing adverse drug reactions to pain medications, while ensuring effective analgesia. Definitive, mass spectrometry-based methods, capable of measuring parent drug and metabolite levels, are the most useful assays for this purpose. Urine drug measurements do not necessarily correlate with serum drug concentrations or therapeutic effects. Therefore, they are limited in their use in monitoring efficacy and toxicity.

View all citing articles on Scopus

View full text

Continuous treatment with the D2 dopamine receptor agonist quinpirole decreases D2 dopamine receptors, D2 dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum

Abstract

Molec. Brain Res.

Eur. J. Pharmac.

Neuropharmacology

Devl Brain Res.

Devl Brain Res.

Eur. J. Pharmac.

Eur. J. Pharmac.

Life Sci.

Brain Res.

Trends Neurosci.

Trends Neurosci.

Eur. J. Pharmac.

Brain Res.

Neuroscience

Neurosci. Lett.

Analyt. Biochem.

Peptides

Neuropharmacology

Biochem. Pharmac.

Neuroscience

Brain Res.

Neurosci. Lett.

Life Sci.

Neuropharmacology

Neuropharmacology

J. biol. Chem.

Computer-assisted video analysis of [3H]-spiroperidol binding autoradiography

J. Neurosci. Meth.

Effects of long-term administration of antidepressants and neuroleptics on receptors in the central nervous system

Cell. molec. Neurobiol.

Interaction of dopamine receptor ligand with subtypes of the opiate receptor

Eur. J. Pharmac.

Expression of dopamine D2 receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudate-putamen

Expl Brain. Res.

The current status of the dopamine hypothesis of schizophrenia

Neuropsychopharmacology

Morphine and δ opiate agonists locally stimulate in vivo dopamine release in cat caudate nucleus

Nature

Continuous treatment with the D₂ dopamine receptor agonist quinpirole decreases D₂ dopamine receptors, D₂ dopamine receptor messenger RNA and proenkephalin messenger RNA, and increases mu opioid receptors in mouse striatum

Computer-assisted video analysis of [³H]-spiroperidol binding autoradiography

Expression of dopamine D₂ receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudate-putamen